Aristotle
Aristotle Core Equity
US Large-cap
Dec 2024 → Mar 2026
Our archive holds 5 letters from this strategy, behind 10 investment theses and positions in 16 companies. Every quote below is copied verbatim from the letter it came from.
5 letters in 3 years · follow all of Aristotle for every strategy.
What it bought and sold
We believe Immunome presents a compelling investment opportunity, driven by its focus on personalized medicine and the promising product story of Varegacestat for desmoid tumors.
We initiated a position in Coherent based on our view that the company sits at the nexus of a key secular growth theme in technology infrastructure, AI-driven data center buildout, with a uniquely defensible position spanning every layer of the
In our opinion, Tempus stands out as a compelling investment opportunity due to its alignment with key secular trends such as AI, Data Analysis and Monetization, and Personalized Medicine.
Also held
Its investment theses
- Immunome Inc.Mar 2026Immunome Inc. is a biotech led by experienced management with a desmoid tumor therapy nearing FDA filing, sizable market potential, and ample cash.
- Performance Food Group CompanyDec 2025Performance Food Group is a diversified, inflation-resilient distributor with defensive end markets, consolidation opportunities, private label upside, and catalysts that support sales and EPS growth.
- APi Group CorporationDec 2025APi Group is a global safety and infrastructure services provider with regulatory-driven recurring revenue, government-backed growth, acquisition-led expansion, and mid-teens earnings targets supporting a premium valuation.
- Coinbase Global, Inc.Dec 2025Coinbase Global is the leading U.S. crypto exchange with strong compliance and security, expanding into derivatives and abroad while shifting toward recurring revenues amid improving regulatory clarity.
- Constellation EnergySep 2025Constellation Energy is a leading player in the U.S. energy sector, focused on producing carbon-free energy through a diverse portfolio, while benefiting from favorable legislation and strong financial performance.
- DexcomSep 2025Dexcom is a strong investment opportunity in the medical device sector, specializing in continuous glucose monitoring systems with significant growth potential and a solid financial foundation.
- Baker HughesSep 2025Baker Hughes is a well-positioned energy technology firm poised to capitalize on rising global demand for natural gas and LNG projects, while improving margins and leveraging its diversified portfolio across energy and industrial sectors.
- Analog DevicesMar 2025Analog Devices is a leading semiconductor company focused on solving complex engineering challenges through innovative analog, mixed-signal, and digital signal processing solutions that enable growth in automotive electrification, automation, and IoT.
- CrowdStrike HoldingsDec 2024CrowdStrike Holdings is well-positioned for substantial growth in the cloud cybersecurity market due to its innovative products, early-mover advantage, and strong customer retention in the face of increasing cyber threats.
- GE AerospaceDec 2024GE Aerospace is poised for strong growth in its commercial engine business, aiming for $10 billion in annual operating profit by 2028 and significant returns to shareholders.